Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01255)
Name
Mitomycin
Synonyms    Click to Show/Hide the Synonyms of This API
mitomycin C; Mitomycin; 50-07-7; Mutamycin; Ametycine; Mitomycin-C; Mitocin-C; Ametycin; Mytomycin; Mitomycinum; Mytozytrex; Mitozytrex; Mitocin C; Mitamycin; MMC; Mitosol; 7-Amino-9alpha-methoxymitosane; NSC-26980; C15H18N4O5; NSC 26980; Mitomycyna C; NCI-C04706; Mito-C; NSC26980; Mit-C; Mitomycine; UNII-50SG953SK6; Mitomycinum C; Mitomycins; CHEBI:27504; RCRA waste number U010; 50SG953SK6; Mitomycyna C [Polish]; MFCD00078109; ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate; Mitomicina; DSSTox_CID_898; DSSTox_RID_75853; DSSTox_GSID_20898; Mitomycin (TN); Mitomycine [INN-French]; Mitomycinum [INN-Latin]; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; Mitomicina [INN-Spanish]; CAS-50-07-7; Muamycin (TN); [1aS-(1a?,8?,8a?,8b?)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-; CCRIS 414; HSDB 3239; Mitomycin (USP/INN); 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester); MLS002702984; (amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate; EINECS 200-008-6; Mitomycin C, Streptomyces caespitosus; RCRA waste no. U010; 7-Amino-9.alpha.-methoxymitosane; Mitonco; Mitoplus; MitoExtra; AI3-26199; Mitomycin [USAN:USP:INN:BAN]; NCGC00095258-01; [(1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2'',3'':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester); Jelmyto (TN); Mitomycin C, Streptomyces caespitosus, Carrier-Free; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP17); CHEMBL105; SCHEMBL3760; CBiol_001927; BSPBio_001267; KBioGR_000607; KBioSS_000607; 1404-00-8; MLS001332654; Mitozytrex (TN) (Supergene); AMETYCIN pound notmitomycin C; GTPL7089; DTXSID2020898; KBio2_000607; KBio2_003175; KBio2_005743; KBio3_001073; KBio3_001074; EX-A501; UGN-101; UGN-102; BCPP000410; Bio1_000213; Bio1_000702; Bio1_001191; Bio2_000464; Bio2_000944; HMS1362O09; HMS1792O09; HMS1990O09; HMS2089F16; HMS3403O09; AMY10316; Tox21_111493; AC-918; BDBM50428658; GR-311; s8146; ZINC30726187; AKOS015895703; Tox21_111493_1; ACN-038344; BCP9000285; CCG-208564; CS-0564; DB00305; KS-5148; IDI1_002219; SMP1_000307; NCGC00163468-02; NCGC00163468-03; NCGC00163468-05; NCGC00163468-06; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))- (9CI); HY-13316; SMR000058401; BCP0726000181; M2320; C06681; D00208; W-5071; AB00918689-03; AB00918689-04; 078M109; Mitomycin C, Antibiotic for Culture Media Use Only; Q-201410; BRD-K59670716-001-02-6; BRD-K59670716-001-06-7; Q19856779; Mitomycin C, contains 2 mg Mitomycin C and 48 mg NaCl; UNII-V03E10691T component NWIBSHFKIJFRCO-WUDYKRTCSA-N; WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KZ L1; Mitomycin C from Streptomyces caespitosus, >=970 mug/mg (USP XXIV); Mitomycin C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture; Mitomycin C from Streptomyces caespitosus, powder, contains NaCl as solubilizer; [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate; [1aS-(1aalpha,8beta,8aalpha,8balpha)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester); Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-; Mitomycin C from Streptomyces caespitosus, >=98% (HPLC), potency: >=970 mug per mg (USP XXIV), gamma-irradiated, suitable for cell culture
Clinical Status
Approved
PubChem CID
5746
Formula
C15H18N4O5
Canonical SMILES
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
InChI
1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
InChIKey
NWIBSHFKIJFRCO-WUDYKRTCSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5746"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 334.33 Topological Polar Surface Area 147
XlogP -0.4 Complexity 757
Heavy Atom Count 24 Rotatable Bond Count 4
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 8
Full List of Drug Formulations (DFMs) Containing This API
          Mitomycin 40mg/vial powder Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Hydroxypropyl Methylcellulose; Mannitol; Poloxamer; Polyethylene Glycol; Water
                   Dosage Form Powder
                   Company Urogen Pharma Ltd
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [1]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [2]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [3]
          Mitomycin 0.2mg/vial For solution Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Mannitol
                   Dosage Form For Solution
                   Company Mobius Therapeutics
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [1]
          Mitomycin 5mg/vial injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Hydroxypropyl Cyclodextrin
                   Dosage Form Injectable
                   Company Supergen
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hydroxyethyl-beta-cyclodextrin DIG Info Solute carrier SLCO1A2 (IC50 = 0.027 %(w/v)) [4]
References
1 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
2 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
3 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
4 Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm. 2012 Sep 4;9(9):2577-81.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.